Skip to main content

Table 1 Patient characteristics

From: Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab

Patient number Age (years) Ethnicity Inhibitors Prior regimen treatment duration Pre-Emicizumab treatment duration Post-Emicizumab Reason to transition to Emicizumab Comorbidities Motor activity level
1 0.4 Caucasian none MTPa 0 0.7 mo difficult venous access, parental decision none normal
2 2 Caucasian none PUPb 0 12 mo difficult venous access, parental decision none normal
3 2 Caucasian none PUPb 0 0.9 mo parental decision none normal
4 3 Caucasian none proph. FVlllc 4 mo 25 mo difficult venous access, parental decision none normal
5 6 Caucasian none proph. FVlllc 4 y, 6 mo 12 mo increasing problems with FVlll administration autism normal
6 9 Caucasian none proph. FVlllc 8 y, 1 mo 3 mo parental decision, better feasibility (reduction of intravenous punctures and physician visits) linguistic development delay normal, very careful parents
7 12 African none proph. FVlllc 10 y, 4 mo 24 mo parental decision Juvenile idiopathic arthritis, asthma normal
8 15 Caucasian none proph. FVlllc 12 y, 7 mo 3 mo parental decision, reduced compliance due to puberty hyperreactive bronchitis normal
9 20 Caucasian none proph. FVlllc 16 y, 5 mo 28 mo change of FVlll required due to availability none reduced
10 3 Caucasian high-titre proph. FVlllc 2 mo 29 mo inhibitors none normal
11 6 Caucasian high-titre ITId, FEIBAe 3 y, 2 mo 24 mo inhibitors ADHDf high
12 9 Caucasian high-titre ITId, FEIBAe 5 y, 5 mo 33 mo inhibitors none normal
13 15 Caucasian high-titre failed ITId, FEIBAe 11 y 40 mo inhibitors none normal
  1. aMTP Minimally treated patient, bPUP Previously untreated patient, proph. cFVlll Prophylactic treatment with FVlll, dITI Immune tolerance induction, eFEIBA Factor Eight Inhibitor Bypassing Activity , fADHD Attention Deficit Hyperactivity Disorder